"-DNA/Roche may have an interest in TPIV investment if the results of a well-conducted clinical trial by Mayo/TPIV overseen by Dr. Perez turn out extremely well. Perhaps DNA foresees the need for a Herceptin replacement, original or bio similar, that surpasses RR, PFS or OS of both, either alone or in combination with other immunotherapy molecules.
K. Dart/Eastern Capital could find its sizeable investment in both TPIV and PPHM fortuitous indeed."
Market Data 
Markets 
AI
